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Severe Combined Immunodeficiency Disease
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To determine whether T cell engraftment and recovery of B cell immunity could be improved, we prospectively
treated15 childrenwith severe combined immunodeficiency disease (SCID)withmegadosesof haplocompatible
CD341 cells and a fixed number of CD31 cells without previousmyeloablative chemotherapy. Evidence of T cell
engraftmentwas seen in 73%of patients (95% confidence interval [CI]5 48%-90%). Engraftmentwasmore likely
in patients with X-linked SCID and in those with evidence of maternal engraftment at the time of diagnosis. In
patients with T cell engraftment, themedian time to development of a CD4 count. 200 cells/mm3 and a phyto-
hemagglutinin response. 50% of control was 1.2 and 4.9 months, respectively. Clearance of preexisting infec-
tions occurred after a median of 2.8 months. B cell function developed in 33% of engrafted patients (95% CI5
14%-61%). The 1-year event-free survival (EFS) ratewas 60% (95%CI5 36%-80%), and the overall survival (OS)
ratewas 87% (95%CI5 61%-98%), with amedian follow-up of 39months. The use ofmegadoses ofCD341 cells
with a fixed number of CD31 cells in nonmyeloablative hematopoietic stem cell transplantation (HSCT) in pa-
tients with SCID is associated with excellent engraftment, T cell recovery, and OS; however, B cell function
does not recover in most patients.
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Severe combined immunodeficiencydisease (SCID)
is a rare disease caused by a group of genetic disorders
with a shared phenotype of deficient T and B lympho-
cyte function that leads to early death from recurrent in-
fections. With the exception of experimental gene
therapy, the only curative therapy for SCIDis allogeneic
hematopoietic stem cell transplantation (HSCT) [1].
Patients with SCID are typically diagnosed based on
the presence of a life-threatening infection, and they
require prompt HSCT to achieve a functional immune
system. In the absence of a matched related donor, T
cell–depleted haplocompatible related donor HSCT isa readily available option [2-4]. Transplantation across
major histocompatibility barriers is associated with
a high rate of graft rejection unless intensive condition-
ing chemotherapy or irradiation is administered [2];
however, the use of myeloablative conditioning in
SCID patients, many of whom have ongoing infections,
has been associated with poor survival rates compared
with nonconditioned HSCT [2,5]. In addition, high-
dose chemotherapy and irradiation may be associated
with significant late effects, includingneurocognitive de-
lay, when administered to infants [6,7]. Finally, some ge-
netic subtypes of SCID are associated with increased
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tion in SCID patients without functioningT cells is the
presence of host natural killer (NK) cells [4], which are
capable of mediating donor hematopoietic stem cell
(HSC) rejection [10,11]. The administration of mega-
doses of CD341 HSCs has been reported to induce
tolerance and abrogate resistance to engraftment,
thereby overcoming major histocompatibility barriers
in HSCT [12]. Another possible explanation for rejec-
tion in patients undergoingT cell–depleted haplocom-
patible HSCT is the variable number of CD31 cells
remaining in the graft after typical CD34 selection
[13,14].Thismay result in insufficientCD31 facilitator
cells to maintain engraftment [15].
A second major issue associated with transplanta-
tion in children with SCID is the reconstitution of B
cell immunity. Most children who undergo noncondi-
tioned haplocompatible HSCT do not experience B
cell recovery [2,3,16,17], resulting in a life-long need
for intravenous immunoglobulin (IVIG) therapy [3].
A lack of conditioning is associated with host myeloge-
nous and B cell chimerism [18,19]. This finding has
been proposed to represent the lack of an HSC graft,
and thereby explains the failure to recover B cell func-
tion. However, in some patients with SCID
undergoing HSCT some degree of HSC engraftment
does occur, even in the absence ofmyeloablative condi-
tioning [20-23]. This phenomenon has been linked to
the administration ofmegadoses of CD341HSCs [22].
Based on the foregoing findings, we hypothesized
that the use of CD34 enrichment to create grafts with
very high doses of CD341 HSCs and a fixed number
of CD31 cells would improve the speed of reconstitu-
tion of T cell numbers and function, and also allow for
the development of B cell engraftment and function. In
addition,wehypothesized that administration of a fixed
dose of CD31 cells would facilitate engraftment with-
out causing significant graft-versus-host disease
(GVHD). To test these hypotheses, we initiated a pro-
spective pilot trial in which patients with SCID but
without a matched related donor were given an infused
megadose ofCD341HSCs ($20106/kg)with afixed
number of CD31 cells without previous myeloablative
conditioning.
PATIENTS AND METHODS
Study Population
Eligible patients were all children who presented
to the University of California San Francisco
(UCSF) Children’s Hospital between June 2000 and
June 2007 with a diagnosis of SCID who did not
have an HLA-matched or HLA-1 antigen–mis-
matched related donor. The patients were assessed
for mutations in the genes encoding the interleukin
(IL) receptor common gamma chain (ILRgc); Januskinase 3; recombinase-activating proteins 1 and 2
(RAG 1 and 2); Artemis; IL-7 receptor a; CD45; the
d, e, and z subunits of CD3; adenosine deaminase; pu-
rine nucleoside phosphorylase; and ZAP70. All pa-
tients met the International Union of Immunological
Societies criteria for the diagnosis of SCID [24]. All
but 2 patients who presented during this time period
were enrolled in the trial. On diagnosis, peripheral
blood mononuclear cells (PBMNC) from each patient
were tested for evidence of maternal engraftment, us-
ing a quantitative polymerase chain reaction (PCR)-
based method involving amplification of genes con-
taining short tandem repeat sequences, as described
previously [25,26]. Any degree of maternal chimerism
was considered positive. The transplantation protocol
was approved by the UCSF Committee on Human
Research, and informed consent was obtained from
the donors and the parents of the patients in accor-
dance with the Declaration of Helsinki.
Donor Peripheral Blood Stem Cell Collection
and Manipulation
Potential donors were tested for HLA-compatibil-
ity at HLA-A, -B, -C, and -DR. For patients with no
evidence of maternal engraftment, either parent could
serve as the HSC donor. For patients with evidence of
maternal engraftment, the mother was the preferred
HSC donor because of presumed host tolerance to-
wardmaternal cells, unless she was otherwise ineligible
for medical reasons. Beginning on the evening of day
25 of conditioning, the donors received 8 doses of
granulocyte colony stimulating factor subcutaneously
(5 mg/kg/dose) every 12 hours. On the afternoon of
day 21 of conditioning, the donors underwent apher-
esis (6 blood volumes per day, 18 L maximum). A min-
imum of 5  1010 mononuclear cells was collected.
CD341 cells were positively selected using the
Baxter Isolex 300i system (Baxter Healthcare, Deer-
field, MA), after which the anti-CD34 bead complex
was eluted from the cells and removed. OKT3, an
anti-T cell monoclonal antibody (mAb), was then
added to the cell preparation, followed by Dynal sheep
antimouse magnetic beads (Invitrogen, Carlsbad, CA).
The cell preparation was reexposed to the magnetic
field to remove residual CD31 cells.
CD341 cells were counted using a phycoerythrin-
conjugated mAb against CD34 and a fluorescein
isothiocyanate–conjugated mAb against CD45, then
evaluated with a FACScan flow cytometer (Becton-
Dickinson, San Jose, CA). 7-Amino-actinomycin D
was added so that gating was performed on only viable
cells. The gating strategy was based on the Interna-
tional Society of Hemotherapy and Graft Engineering
method [27]. Stem cells had low side scatter, low to in-
termediate forward scatter, and low to intermediate
amounts of CD45 expression.
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were evaluated for the presence of T cells using a phy-
coerythrin-conjugated mAb against CD3 and a FACS-
can flow cytometer. If the CD3 count was above the
goal dose, then an additional cycle of T cell depletion
was performed. If the CD3 count was below the goal
dose, then CD31 cells were added from the CD34-
fraction product.
Transplantation Regimen
Originally, patients with NK1 phenotypes were
given fludarabine (Flu) at a dose of 25 mg/m2/day on
days 26 through 22. When it became obvious that
Flu did not inhibit NK cell activity [28], the protocol
was amended. For patients with no maternal engraft-
ment or maternal engraftment without evidence of
GVHD, no conditioning was administered. For those
with maternal engraftment and evidence of GVHD,
Flu was administered at a dose of 30 mg/m2/day on
days24,23, and22. No GVHD prophylaxis was ad-
ministered.
The goal for the infused CD34 dose was $ 20 
106/kg of the recipient’s body weight. The initial
goal for the infused CD3 dose was 3  104/kg for pa-
tients without maternal engraftment, later amended to
6  104/kg. For patients with maternal engraftment,
the goal for the infused CD3 dose was # 3  104/kg.
Donor lymphocyte infusions (DLIs) were prospec-
tively prepared from the negative fraction of the
CD341 selection by cryopreservation. DLI could be
administered at 4-week intervals for patients with
persistent life-threatening infections and no evidence
of GVHD.
In the event of graft rejection, if a suitably matched
(7 or 8 of 8 HLA matches, with DR mismatch not
allowed) unrelated donor was located, then the patient
would undergo myeloablative HSCTwith intravenous
busulfan (Bu; targeted to a Css of 600 ng/ml), followed
by Flu (40 mg/m2/day intravenously for 4 days), and
rabbit antithymocyte globulin (ATG; 0.5 mg/kg
once, then 2 mg/kg for 3 days). If an unrelated donor
was not available, then the patientwould undergo a sec-
ond T cell–depleted haplocompatible HSCT with the
samemyeloablative conditioning. But if the patient was
deemed too unstable for myeloablation, because of
infection or end-organ toxicity, then a second
nonmyeloablativeHSCTcould be performed, with cy-
clophosphamide (Cy; 60 mg/kg intravenously for 2
days) administered to inhibit NK cell function [29].
Analysis of Engraftment and Immunologic
Parameters
Posttransplantation donor chimerism of CD31,
CD191, and CD14/151 cells was determined using
a quantitative PCR-based method involving amplifica-
tion of genes containing short tandem repeat sequences[25,26]. NK cell chimerism was not tested. Lympho-
cyte subsets were assessed by flow cytometry and com-
pared with normal values for age [30]. T cell function
was assessed by 3H-thymidine incorporation in re-
sponse to phytohemagglutinin (PHA), and reported
as a percentage of stimulated immunologically compe-
tent control lymphocytes tested simultaneously (Mayo
MedicalLaboratories, Rochester,MN).Tcell receptor
excision circle and CD45 RA/RO analyses were not
performed. B cell function was evaluated based on the
ability to produce IgM levels $ 50 mg/dL (normal
range, 43-200 mg/dL), appropriate isohemagglutinin
(ISH) levels detectable at a $ 1:8 dilution, and, when
appropriate, specific antibodies after vaccination.
Supportive Care
Active infections at the time of diagnosis were
treated with appropriate antimicrobial therapies that
were continued until evidence of resolution was seen.
These therapies included high-dose cotrimoxazole (5
mg/kg/dose of trimethoprim component 4 times daily)
for patients with Pneumocystis jirovecii pneumonia
(PCP), ganciclovir (5 mg/kg/dose twice daily) and/or
foscarnet (90 mg/kg/dose twice daily) for patients with
cytomegalovirus (CMV), and inhaled ribavirin (6 g by
continuous inhalation over 8 hours) for patientswith re-
spiratory syncytial virus (RSV). Parainfluenza, rhinovi-
rus, and rotavirus were managed with supportive care.
Patients received cotrimoxazole (5 mg/kg/day
divided twice daily for 3 consecutive days per week)
for PCP prophylaxis and acyclovir (800 mg/m2/day by
mouth in divided doses) for herpes simplex virus pro-
phylaxis until the CD4 count was $ 200 cells/mm3
and the PHA level was $ 50% of control. Patients re-
ceived IVIG (400 mg/kg) every 3 weeks until the IgM
was $ 50 mg/dL and the ISH titers were $ 1:8. CMV
antigen orPCRmonitoringwas performedweekly until
discharge and then every 2 weeks until T cell recovery
occurred. Epstein-Barr virus PCR was obtained every
2 weeks until 3 months after HSCT. Acute and chronic
GVHD (aGVHD, cGVHD) were graded using stan-
dard criteria [31,32].
Statistical Considerations
Event-free survival (EFS) and overall survival (OS)
were estimated by the Kaplan-Meier method using
log-rank tests and SPSS version 16.0 (SPSS Inc,
Chicago, IL). Events were defined as second transplan-
tation or death. Fisher’s exact test was used to detect
statistical differences between groups.
RESULTS
Patient Characteristics
Between Octber 2001 and May 2007, 15 patients
were enrolled (Table 1). Of note, 4 patients
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these 4 cases, mutations were identified in genes
known to be responsible for causing SCID, including
1 patient (UPN 446) with the same RAG mutation as
her identical twin (UPN 441). In 2 of the 4 cases
(UPN 1057 and 1088), maternally engrafted T cells
were present at diagnosis. In the other 2 cases, the de-
velopment of autologous T cells may have been driven
by the presence of active infection [33-35]. The me-
dian age at HSCT was 5.7 months (range, 0.5 to
16.5 months). Maternal engraftment was detected in
53% (8/15) of patients at the time of diagnosis, and
13% (2/15) had evidence of maternal GVHD.
Table 2 summarizes transplantation characteris-
tics. Most donors required central venous access and
2 days of collection for the apheresis procedure, how-
ever, no donor experienced any serious adverse events.
The median dose of CD341 cells infused was 23.5 
106/kg (range, 18.4 to 61.6  106/kg). The median
dose of CD31 cells infused was 3 x 104/kg (range, 1
to 6  104/kg). Three patients received 1 or more
DLI at a dose of 3  104 CD31 cells/kg starting 12
to 17 weeks after HSCT.
Engraftment
Table 3 presents transplantation outcomes. Evi-
dence of T cell engraftment was seen in 73% of
the patients (95% confidence interval [CI] 5 48%-
90%). All 7 patients with X-linked SCID had T
cell engraftment (100%; 95 CI 5 60%-100%) com-
pared with 4/8 patients with NK1 SCID (50%; 95%
CI 5 22%-78%) (P 5 .08). All 8 patients with
evidence of maternal engraftment at the time of
diagnosis successfully engrafted (100%; 95% CI 5
63%-100%), compared with 3 of 7 patients withoutmaternal engraftment (43%; 95% CI 516%-75%)
(P 5 .03). One patient (UPN 1231) with T-B1NK1
SCID rejected a paternal haplocompatible HSCT
but subsequently engrafted after a maternal haplocom-
patible HSCT with nonmyeloablative conditioning
(Cy alone). One patient (UPN 1095) with T-B1NK1
SCID rejected a maternal haplocompatible HSCT
but subsequently engrafted after a paternal haplocom-
patible HSCT with myeloablative conditioning. Two
siblings with RAG deficiency rejected their haplocom-
patible HSCTs but subsequently engrafted after mye-
loablative matched unrelated donor HSCT.
In those patients who did not undergo a second
myeloablative HSCT, evidence of significant B cell
engraftment (. 5%) was seen in only 25% (95% CI
5 8%-54%). All 3 patients with B cell engraftment
had GVHD after HSCT.
GVHD
aGVHDwas seen in 58%of patientswho engrafted
after a nonmyeloablative HSCT (95% CI 5 32%-
81%). All of these cases were grade II and resolved
with standard therapy, except for 2 patients who devel-
oped progressive onset cGVHD (17%; 95%CI5 4%-
46%).The development of aGVHDwas not associated
with either the presence of pretransplantationmaternal
engraftment or the CD31 cell dose administered. The
2 patients with progressive cGVHD required treat-
ment with immunosuppressive medication for 15
months before complete resolution occurred.
T Cell Reconstitution
As shown in Table 4, in the 12 patients with T cell
engraftment after nonmyeloablativeHSCT, themedian
time from HSCT to achieve a CD4 count . 200 cells/Table 1. Characteristics at time of diagnosis of SCID
UPN Sex Gene CD3 CD4 CD19 CD16/56
PHA
(%)
Engraft
(%) Infection
Age at HSCT
(months)
441 F RAG 45 39 0 110 3 0 None 7.9
446 F RAG 218 210 3 28 3 0 PCP 9.2
472 F Unknown 2 0 106 68 0 0 Paraflu PNA + Rota + C albicans mycetoma 15
483 F RAG 0 0 0 954 0 0 RSV PNA + Rota 16.5
500 M RAG 157 4 3 925 11 1 CMV (disseminated) 4.7
1088 F Artemis 10660 9348 0 4592 9 2* CMV (disseminated) 5.7
1095 F Unknown 3712 3654 1770 171 0 0 Enterovirus enteritis + rhinovirus 15.5
1231 F Unknown 5 0 630 330 1 0 Paraflu PNA 6.1
401 M ILRgc 121 16 3065 13 0 11 PCP 6.1
455 M ILRgc 3 2 828 18 0 1 None 2.2
1056 M ILRgc 314 0 4086 0 0 5 PCP 5.7
1057 M ILRgc 1773 886 3656 111 1 24 PCP 5.7
1091 M ILRgc 16 16 462 5 3 0 RSV PNA + Rota 5.7
1142 M ILRgc 0 0 808 52 0 1 None 0.5
1148 M ILRgc 30 20 0 1 0 87* Rhinovirus + Enterobacter spp 2.6
CD3 indicates absolute CD3 count, cells/mm3 (lower limit of normal: 1600); CD4, absolute CD4 count, cells/mm3 (lower limit of normal, 1000); CD19,
absolute CD19 count, cells/mm3 (lower limit of normal, 600); CD16/56, absolute NK cell count, cells/mm3 (lower limit of normal, 100); PHA, prolif-
eration in response to phytohemagglutinin (% of control value); Engraft, maternal engraftment of peripheral blood mononuclear cells; PCP, Pneumocystis
jirovecci pneumonia; Paraflu, parainfluenza 1-3; Rota, rotavirus; PNA, pneumonia.
*Clinical GVHD present at diagnosis.
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UPN Phenotype Donor
Antigen
mismatch* Conditioning Source
CD34
(106/kg)
CD3
(104/kg)
DLI dose
(104/kg)
441 T-B-NK+ Mother 3 FLU125 PBSC 31.8 3 0
446 T-B-NK+ Mother 3 FLU125 PBSC 19.7 2 0
472 T-B+NK+ Mother 3 None PBSC 23.5 6 0
483 T-B-NK+ Mother 3 None PBSC 30 6 0
500 T-B-NK+ Mother 3 None PBSC 61.6 3 0
1088 T-B-NK+ Mother 4 FLU90 PBSC 20 1 3, 3
1095 T-B+NK+ Mother 4 None PBSC 27.6 6 0
1231 T-B+NK+ Father 4 None PBSC 22.7 6 0
401 T-B+NK- Mother 4 None PBSC 19 1 0
455 T-B+NK- Mother 4 None PBSC 23.4 1 0
1056 T-B+NK- Mother 3 None PBSC 28.2 3 0
1057 T-B+NK- Mother 3 None PBSC 28.3 3 0
1091 T-B+NK- Mother 4 None PBSC 20 1 3
1142 T-B+NK- Father 4 None PBSC 18.4 6 0
1148 T-B+NK- Mother 4 FLU90 PBSC 30.1 1 0
Second transplantations
441 T-B-NK+ MUD 0 BU + FLU160 + rATG Marrow 6† ND 0
446 T-B-NK+ MUD 0 BU + FLU160 + rATG Marrow 6† ND 0
1095 T-B+NK+ Father 4 BU + FLU160 + rATG PBSC 30.8 6 0
1231 T-B+NK+ Mother 4 CY120 PBSC 26.2 3 3
Flu indicates fludarabine; Bu, busulfan; rATG, rabbit antithymocyte globulin; Cy, cyclophosphamide; PBSC, peripheral blood stem cell; MUD, 8/8 HLA-
matched unrelated donor.
*Eight loci tested (HLA-A, -B, -C, -DR).
† 108 total nucleated cells/kg.mm3 was 1.2 months (range, 0.5-8.3 months), and that
to achieve a CD4 count . 400 cells/mm3 was 3.7
months (range, 0.9-12 months). The median time
from HSCT to development of a PHA response .
50% of control was 4.9 months (range, 3.4-12.6
months), and that to development of a PHA response
. 90% of control was 9.8 months (range, 5.5-18.5
months). The median time to development of a conco-
navalin A response and a pokeweedmitogen response.
50% of control were 8.4 months (range, 3.9-18.5
months) and 6.2 months (range, 5.5-14.2 months), re-
spectively. There was no increase in the rapidity of de-
velopment of a CD4 count. 200 cells/mm3 and a PHA
response . 50% of control with an increased dose ofinfused CD31 cells: median of 1.1 and 6.1 months, re-
spectively, for 1  104 T cells/kg (excluding the 2 pa-
tients who received DLI); median of 1.1 and 3.5
months, respectively, for 3 104T cells/kg; andmedian
of 2.4 and 6.3 months, respectively, for 6 104 T cells/
kg. Despite successful T cell reconstitution, 1 patient
(UPN 1095) developed autoimmune hemolytic anemia
5.5 months after a second myeloablative HSCT, for an
overall incidence of 8% (95% CI 5 1%-38%).
B Cell Reconstitution
As shown in Table 4, of the 12 patients with
T cell engraftment after nonmyeloablative HSCT, 6
(50%; 95% CI 5 25%-75%) developed an IgM levelTable 3. Clinical outcome after haplocompatible HSCT for children with SCID
UPN Gene
Engraftment,
months
% Donor
CD3*
% Donor
CD19*
% Donor
CD14/15*
aGVHD
grade
cGVHD
location
Alive
(months)†
472 Unknown 39 90 0 1 0 0 Yes (68)
483 RAG 5 98 98 99 2 0 No (6)
500 RAG 52 99 1 2 0 0 Yes (56)
1088 Artemis 3 88 53 2 2 0 No (7)
401 ILRgc 89 98 3 2 0 0 Yes (95)
455 ILRgc 60 97 3 1 2 0 Yes (74)
1056 ILRgc 34 96 0 0 2 Skin Yes (39)
1057 ILRgc 34 98 0 0 2 0 Yes (39)
1091 ILRgc 31 79 0 0 0 0 Yes (33)
1142 ILRgc 21 97 3 3 2 Skin Yes (24)
1148 ILRgc 19 100 100 100 2 0 Yes (22)
Patient who engrafted after second nonmyeloablative HSCT
1231 Unknown 6 76 1 1 0 0 Yes (10)
Patients who engrafted after myeloablative HSCT
441 RAG 58 99 97 17 0 0 Yes (73)
446 RAG 58 95 88 12 0 0 Yes (73)
1095 Unknown 24 99 46 3 0 0 Yes (31)
Engraftment indicates post-HSCT time to most recent engraftment analysis; aGVHD, acute graft-versus-host disease; cGVHD, chronic GVHD.
*At last follow-up;
†From last HSCT.
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UPN
CD4 > 200
cells/mm3,
months
CD4 > 400
cells/mm3,
months
PHA >
50%,
months
PHA >
90%,
months
CON A >
50%,
months
PWM >
50%,
months
IgM >50
mg/dL,
months
ISH $
1:8,
months
Tetanus
antibody > 0.15
U/mL, months IVIG?
472 2.5 NR 3.7 NR 12.9 12.9 12.9 12.9 39.6 No
483 0.5 2.8 6.4 NR 6.4 6.4 NR NR ND NA
500 1.8 8.7 3.4 14.2 5.5 5.5 8.7 34.2 41.8 No
1088 3.7 4.4 3.4 5.5 5.9 5.7 ND ND ND NA
401 1.2 1.2 6.2 6.2 14.2 14.2 34.4 NR ND Yes
455 1.1 1.1 3.4 12 12 5.6 46.1 46.1 * No
1056 0.6 12 10.3 10.3 10.3 10.3 NR NR ND Yes
1057 1.1 3.5 3.5 5.5 5.5 5.5 NR NR ND Yes
1091 0.9 0.9 10.5 NR 10.5 10.5 NR NR ND Yes
1142 2.2 3.8 12.6 18.5 18.5 6.2 NR NR ND Yes
1148 0.8 9.2 6.1 9.2 3.9 6.1 5.5 13.1 16.3 No
Patient who engrafted after second nonmyeloablative HSCT
1231 8.3 NR 6.2 NR 6.2 6.2 5.3 NR ND Yes
Patients who engrafted after myeloablative HSCT
441 3.4 7.5 4.1 6.6 6.6 12.1 35 15.2 46.5 No
446 4.8 6.6 4.1 6.6 6.6 12.1 35 15.2 46.5 No
1095 8.8 12.7 4.1 5.6 5.6 4.1 12.7 NR ND Yes
CON A, conconavalin A; PWM, pokeweed mitogen; IVIG?, Patient receiving IVIG at date of last follow-up; NR, not reached; ND, not done.
*Testing in progress.$ 50 mg/dL at a median of 10.8 months (range, 5.5-
46.1 months) after HSCT. Four patients (33%; 95%
CI 5 14%-61%) developed an ISH $ 1:8 and were
able to stop IVIG replacement at a median of 23.7
months (range, 12.9-46.1 months) after HSCT.
These patients also developed specific antibodies to
tetanus, as well as other vaccines (including diphthe-
ria, polio, and 7-valent pneumococcus; data not
shown); 1 of these patients (UPN 455) was still un-
dergoing testing at the time of this writing. These in-
clude 3 patients with minimal to no donor B cell
chimerism. Only 1 patient with X-linked SCID
(UPN 1148) developed B cell function after HSCT,
as reported previously [36].
Clearance of Preexisting Infection
Most of the patients (80%; 12/15) were diagnosed
with SCID after the development of 1 or more severe
infections (Table 1). Four patients had PCP, 1 patient
had Enterobacter aerogenes bacteremia, and 1 patient
had Candida albicans fungemia associated with an atrial
mycetoma. Two patients had disseminated CMV dis-
ease with retinitis, and 4 patients had significant respi-
ratory distress from parainfluenza or RSV pneumonia,
including 1 patient treated with intravenous ribavirin
(33 mg/kg on day 1, followed by 16 mg/kg/dose every
6 hours for 4 days, then 8 mg/kg/dose every 8 hours
until response [37]; obtained through compassionate
release from ICN Pharmaceuticals, Costa Mesa, CA)
due to failure of inhaled ribavirin.
The 6 patients with disseminated CMV or viral
pneumonia had active infections at the time of trans-
plantation despite continued therapy. Of these, 5
patients had T cell engraftment after their first non-
myeloablative HSCT, and all 5 of them cleared their
viral infection at a median of 2.8 months (range, 1.6-10.5 months) from HSCT. The other patient cleared
his 2 viral infections after a second HSCT.
Survival
All 4 patients with graft rejection were successfully
engrafted with second transplants and are currently
surviving disease-free. Therefore, the 3-year EFS after
HSCT was 60% (95% CI 5 36%-80%), and the
OS after HSCT was 87% (95% CI 5 61%-98%)
(Figure 1). One patient (UPN 1088) died from Pseudo-
monas sepsis. Another patient (UPN 483) was lost to
follow-up but was reported to have died of unknown
causes after her parents returned to their home country
against medical advice. Median follow-up of the sur-
viving patients was 39 months (range, 10-95 months)
from last transplantation.
DISCUSSION
In this prospective pilot study, the use of mega-
doses of haplocompatible CD341 HSCs with a fixed
dose of CD31 cells was associated with a 73% rate of
T cell engraftment despite the lack of myeloablative
conditioning. This compares favorably with retrospec-
tive reports of nonconditioned haplocompatible
HSCT in SCID. We previously reported a 40% rate
of T cell engraftment in patients given standard doses
of nucleated marrow cells that were T cell–depleted
with soybean agglutinin and sheep red blood cells
(range, 0.5-5.4  108/kg) [2], whereas Fischer et al.
[19] reported a 50% rate of engraftment. Not surpris-
ingly, T cell engraftment was easier to obtain in pa-
tients without NK cells or with evidence of maternal
engraftment at the time of diagnosis.
Unlike the report by Bielorai et al. [22], we found
that the use of megadose CD341 HSCs was not
Biol Blood Marrow Transplant 14:1125-1133, 2008 1131Megadose CD341 Cells in Haplocompatible HSCT for SCIDassociated with a high rate of B cell engraftment or
function. Bielorai et al. [22] hypothesized that another
explanation for the development of multilineage en-
graftment in their 3 patients was the universal develop-
ment of GVHD, whichmay have led to the destruction
of hostHSCs shortly after stem cell infusion. This con-
cept has also been demonstrated in an experimental
mouse model of SCID [38]. Of note, although all 4 of
our patients with B cell engraftment did have evidence
of aGVHD after HSCT, not all patients with aGVHD
developed B cell engraftment. This indicates that in-
duction of aGVHDmay not be a reliable (or necessar-
ily safe) method for achieving B cell engraftment. The
sole patient with X-linked SCID who developed B cell
engraftment and function after HSCT also had pancy-
topenia at diagnosis due to a hemophagocytic reaction
in his bone marrow [36]. This provides further evi-
dence that creation of niches within either the hemato-
poietic stem cell or B lineage compartments may be
necessary to eventually achieve a higher rate of B cell
engraftment and function. Of note, several patients in
this trial developed evidence of B cell functional recon-
stitution despite very little evidence of donor B cell en-
graftment. In patients with B1 SCID, a possible
explanation for this is that the immunoglobulins are
produced by host B cells with donor T cell support,
as has been reported previously [18]. Alternatively,
the immunoglobulins may be of donor origin; a gene
therapy trial for ILRgc-SCID has demonstrated that
very low levels of gene-corrected B cells allow adequate
immunoglobulin production [39]. Further studies with
immunoglobulin allotypic markers may help clarify
these findings, which may vary between patients de-
pending on the role of the specific genetic defect on
autologous B cell lymphopoiesis.
Some components of post-HSCT immune recon-
stitution recovered rapidly in this trial; a normal CD4
count was achieved at a median of 3.7 months after
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Figure 1. Kaplan-Meier overall survival and EFS estimates. The proba-
bilities of OS and EFS for the 15 patients with SCID undergoing nonmye-
loablative T cell–depleted haplocompatible megadose peripheral blood
stem cell transplantation with a fixed dose of CD31 cells.HSCT. Our previous experience without megadoses
of CD341 HSCs retrospectively demonstrated
a mean time to CD4 normalization after HSCT of
10.7 months [2]. However, we did not find that mega-
doses of CD341 HSCs improved the time to T cell
functional recovery; the median time to normalization
was 9.8 months. Our experience without megadoses of
CD341 HSCs demonstrated an average time to PHA
normalization of 7.3 months [2], whereas Haddad
et al [16] reported achieving ‘‘normal’’ T cell function
at amedian of 8.7months. Few other studies have care-
fully reported the kinetics of T cell recovery after non-
myeloablative haplocompatibleHSCT in patients with
SCID. When B cell functional recovery did occur, the
median time of 23.5 months was comparable to previ-
ously reported results of 14.9-22 months [2,16].
The OS of the patients in this prospective trial was
87%, which compares favorably to retrospective re-
ports of nonmyeloablative haplocompatible HSCT
for treatment of SCID with OS ranging from 46%
to 78% [2-4]. All but 3 patients were older than age
3.5 months at the time of transplantation, and all but
3 had evidence of significant infection at the time of
HSCT; both variables have been shown to be associ-
ated with poor outcome [3,4,40]. Because the clear-
ance of preexisting viral infection depends on the
ability to successfully achieve donor T cell engraft-
ment and recovery, we propose that the use of mega-
doses of CD341 HSCs with a fixed dose of CD31
cells favorably affected the OS of our patients. Im-
provements in infection monitoring, prophylaxis,
and treatment also likely contributed to the excellent
OS in this more recent population of patients,
however.
It has been retrospectively reported that unrelated
adult donors [5,40-42] or umbilical cord blood [43,44]
can provide a source of HSCs for patients with SCID.
Most studies involving these sources used myeloabla-
tive conditioning to successfully achieve engraftment.
In addition, identifying a well-matched unrelated do-
nor can take several months, and an umbilical cord
blood unit generally can be found more quickly. How-
ever, as seen in most of our patients, presence of an ac-
tive infection at the time of diagnosis and HSCT is the
primary reason that many patients with SCID cannot
tolerate prolonged searches and/or myeloablative con-
ditioning regimens. Therefore, in the absence of
a matched sibling donor, the rapid availability of and
excellent outcomes after megadoses of CD341 cells
in T cell–depleted haplocompatible HSCT make it
an attractive option for patients with SCID.
In summary, this prospective pilot trial tested the
hypothesis that megadoses of CD341 cells with a fixed
dose of CD31 cells would result in improved T cell
and B cell reconstitution in patients with SCID under-
going nonmyeloablative HSCT. The trial was limited
by small numbers of patients, as would be expected in
1132 Biol Blood Marrow Transplant 14:1125-1133, 2008C. C. Dvorak et al.this rare disease. Nonetheless, we found that the use of
megadoses of CD341 HSCs with a fixed number of
CD31 cells was associated with an excellent OS and
rate of engraftment, as well as rapid recovery of T
cell numbers. The more rapid recovery of T cell num-
bers in this trial compared with historic controls,
despite a small fixed dose of T cells infused with the
graft, along with the lack of a dose effect of the infused
T cells, argue that these are not peripherally expanded
T cells. Instead, it appears that the use of megadoses of
CD341 cells allows more cells to undergo lymphoid
differentiation. However, further elucidation of the
origin of the T cells in patients receiving megadoses
of CD341 in HSCT will require use of T cell receptor
excision circle and CD45 RA/RO analysis, as we are
prospectively measuring in the successor to this trial.
Unfortunately, the rate of recovery of T cell function
was not significantly different from historic reports,
and B cell function failed to develop in most of the
patients. Therefore, although megadoses of haplo-
compatible CD341 HSCs are a useful component of
nonmyeloablative HSCT for infants with SCID, fu-
ture attempts to improve engraftment and B cell recov-
ery likely will need to use novel techniques to inhibit
host NK cells and create open niches in the bone mar-
row microenvironment if conventional chemotherapy
and/or irradiation are to be avoided.
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